[go: up one dir, main page]

FI971532L - HER4, ihmisen reseptorityrosiinikinaasi, joka kuuluu ryhmään ihokasvutekijäreseptorit - Google Patents

HER4, ihmisen reseptorityrosiinikinaasi, joka kuuluu ryhmään ihokasvutekijäreseptorit Download PDF

Info

Publication number
FI971532L
FI971532L FI971532A FI971532A FI971532L FI 971532 L FI971532 L FI 971532L FI 971532 A FI971532 A FI 971532A FI 971532 A FI971532 A FI 971532A FI 971532 L FI971532 L FI 971532L
Authority
FI
Finland
Prior art keywords
her4
belongs
group
growth factor
tyrosine kinase
Prior art date
Application number
FI971532A
Other languages
English (en)
Swedish (sv)
Other versions
FI971532A7 (fi
FI971532A0 (fi
Inventor
Gregory D Plowman
Mohammed Shoyab
Clay Siegall
Jean-Michel Culouscou
Ingegerd Hellstrom
Karl E Hellstrom
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of FI971532A0 publication Critical patent/FI971532A0/fi
Publication of FI971532A7 publication Critical patent/FI971532A7/fi
Publication of FI971532L publication Critical patent/FI971532L/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/4756Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/485Epidermal growth factor [EGF], i.e. urogastrone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • G01N2333/4756Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI971532A 1994-10-14 1995-10-10 HER4, ihmisen reseptorityrosiinikinaasi, joka kuuluu ryhmään ihokasvutekijäreseptorit FI971532L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32344294A 1994-10-14 1994-10-14
PCT/US1995/013524 WO1996012019A2 (en) 1994-10-14 1995-10-10 Her4 human receptor tyrosine kinase or the epidermal growth factor receptor family

Publications (3)

Publication Number Publication Date
FI971532A0 FI971532A0 (fi) 1997-04-11
FI971532A7 FI971532A7 (fi) 1997-06-11
FI971532L true FI971532L (fi) 1997-06-11

Family

ID=23259216

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971532A FI971532L (fi) 1994-10-14 1995-10-10 HER4, ihmisen reseptorityrosiinikinaasi, joka kuuluu ryhmään ihokasvutekijäreseptorit

Country Status (9)

Country Link
EP (1) EP0787187A1 (fi)
JP (1) JPH10507362A (fi)
AU (1) AU3963295A (fi)
CA (1) CA2202533A1 (fi)
FI (1) FI971532L (fi)
IL (1) IL115642A0 (fi)
MX (1) MX9702664A (fi)
NO (1) NO971686L (fi)
WO (1) WO1996012019A2 (fi)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9805398A (en) * 1997-10-15 1999-05-03 Children's Medical Center Corporation Novel human egf receptors and use thereof
WO1999023209A2 (en) * 1997-10-31 1999-05-14 Georgetown University Medical Center ErbB-4 TARGETED RIBOZYMES
WO2004068931A2 (en) 2003-02-07 2004-08-19 Protein Design Labs Inc. Amphiregulin antibodies and their use to treat cancer and psoriasis
AU2009314534B2 (en) 2008-11-12 2014-06-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of ERBB4 as a prognostic and therapeutic marker for melanoma

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2103323A1 (en) * 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase

Also Published As

Publication number Publication date
WO1996012019A2 (en) 1996-04-25
IL115642A0 (en) 1996-01-19
MX9702664A (es) 1997-06-28
EP0787187A1 (en) 1997-08-06
FI971532A7 (fi) 1997-06-11
JPH10507362A (ja) 1998-07-21
AU3963295A (en) 1996-05-06
FI971532A0 (fi) 1997-04-11
NO971686L (no) 1997-06-16
WO1996012019A3 (en) 1996-08-15
NO971686D0 (no) 1997-04-11
CA2202533A1 (en) 1996-04-25

Similar Documents

Publication Publication Date Title
FI935175A7 (fi) Tyrosiinikinaasin HER4-humaanireseptori
CY2008003I2 (el) Ανθρωπινα μονοκλωνικα αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης
BR9610823A (pt) Derivados de pirimidina como antagonistas do receptor
FI920027A7 (fi) Fibroblastikasvutekijöiden reseptoreita
EP0809499A4 (en) Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine
WO1999019488A8 (en) Novel human egf receptors and use thereof
FI20040649A7 (fi) Bisykliset yhdisteet, jotka pystyvät inhiboimaan epidermisen kasvutekijäreseptoriperheen tyrosiinikinaaseja
FI924963A7 (fi) Tärkkelyskuidut, menetelmä niiden valmistamiseksi sekä niiden käyttö
DK0772905T3 (da) Modtager med direkte konvertering
DE19681389T1 (de) Dosierungsform, umfassend Oxybutynin
MX9204425A (es) Derivados de quinazolina como inhibidores de la acetilcolinesterasa.
EE03482B1 (et) Kinasoliiniderivaadid, nende valmistamismeetod ja kasutamine
FI972583A7 (fi) Tetrasyklisiä spiroyhdisteitä, menetelmä niiden valmistamiseksi ja nii den käyttö 5HT1D-reseptoriantagonisteina
AU1518595A (en) Antagonists to insulin receptor tyrosine kinase inhibitor
DE19653645A1 (de) Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
BR9711350A (pt) Derivados de acilaminoalquenileno como antagonistas a nk1 en nk2
GB9001466D0 (en) Extracellular form of the human fibroblast growth factor receptor
FI971532L (fi) HER4, ihmisen reseptorityrosiinikinaasi, joka kuuluu ryhmään ihokasvutekijäreseptorit
DE69933057D1 (de) Analoge des humanen basischen fibroblasten-wachstumsfactors
FI910309A7 (fi) Difunktionaalisten halogeeniorgaanoalkuaineimidien uusi synteesi, joka alkuaine kuuluu ryhmän IV pääryhmään lukuunottamatta hiiltä
FI971528L (fi) Pyrrolyylitetrahydrobentsokinoksaliinidionit, niiden valmistus ja käyttö glutamaattireseptoriantagonisteina
TR199600434A1 (tr) Ikame edilmis 8-klorokinolin'lerin ikame edilmis 8-hidrosikinolin'lere cevrilmesi.
FI943376L (fi) Fenyyli-imidatsolidinonijohdannaiset, menetelmä niiden valmistamiseksi ja niiden käyttö 5HT3-reseptoriantagonisteina
EP0695802A3 (en) Related receptor of the human corticotropin-releasing hormone receptor
KR970051980U (ko) 접철식 화분대 겸용 발코니 난간

Legal Events

Date Code Title Description
MA Patent expired